Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Protalix Biotherapeutics Inc

Healthcare US PLX

1.98USD
0.02(1.02%)

Last update at 2026-06-09T20:10:00Z

Day Range

1.962.02
LowHigh

52 Week Range

1.193.55
LowHigh

Fundamentals

  • Previous Close 1.96
  • Market Cap131.31M
  • Volume460291
  • P/E Ratio20.00
  • Dividend Yield12.09%
  • EBITDA14.73M
  • Revenue TTM63.62M
  • Revenue Per Share TTM1.02
  • Gross Profit TTM 28.05M
  • Diluted EPS TTM0.09

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -14.39700M -27.58200M -6.52300M -18.27600M -26.45700M
Minority interest - - - - -
Net income -14.92700M -33.98500M -14.89200M -26.24200M -26.45700M
Selling general administrative 13.58M 4.02M 5.09M 5.97M 1.94M
Selling and marketing expenses 25.29M 16.75M 16.24M 15.87M 8.98M
Gross profit 28.05M 22.00M 52.02M 43.80M 24.94M
Reconciled depreciation 1.09M 1.12M 1.30M 1.62M 1.67M
Ebit -13.01400M -20.46200M 1.85M -10.71700M -20.44300M
Ebitda -10.78200M -20.06100M 3.15M -8.69300M -18.77200M
Depreciation and amortization 2.23M 0.40M 1.30M 2.02M 1.67M
Non operating income net other - - - -7.55900M -7.14900M
Operating income -13.01400M -20.46200M 1.85M -10.71700M -19.30800M
Other operating expenses 60.65M 58.81M 60.19M 65.41M 53.55M
Interest expense 2.53M 7.52M 9.67M 7.97M 7.68M
Tax provision 0.53M - - - -
Interest income 1.15M 0.40M 0.44M 0.41M 0.54M
Net interest income -1.38300M -7.12000M -9.23300M -7.55900M -7.14900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.53M 6.40M 8.37M 7.97M 0.54M
Total revenue 47.64M 38.35M 62.90M 54.69M 34.24M
Total operating expenses 41.06M 42.46M 49.31M 54.52M 44.25M
Cost of revenue 19.59M 16.35M 10.87M 10.89M 9.30M
Total other income expense net -1.38300M -7.12000M -8.36900M -7.55900M -7.14900M
Discontinued operations - - - - -
Net income from continuing ops -14.92700M -27.58200M -6.52300M -18.27600M -26.45700M
Net income applicable to common shares -14.92700M -27.58200M -6.52300M -18.27600M -26.45700M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 55.79M 73.67M 67.93M 45.39M 61.13M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.54M 1.28M 2.10M 0.70M 1.88M
Total liab 66.43M 79.70M 94.97M 115.71M 114.01M
Total stockholder equity -10.64000M -6.03600M -27.03700M -70.32200M -52.88100M
Deferred long term liab - - - - -
Other current liab 12.27M 16.43M 13.93M 11.90M 10.27M
Common stock 0.05M 0.05M 0.04M 0.01M 0.15M
Capital stock 0.05M 0.05M 0.04M 0.01M 0.15M
Retained earnings -389.86100M -374.93400M -347.35200M -340.82900M -322.55300M
Other liab 1.64M 14.26M 4.03M 20.05M 36.39M
Good will - - - - -
Other assets 1.27M 2.08M 0.00737M 1.96M 1.76M
Cash 17.11M 38.98M 18.27M 17.79M 37.81M
Cash and equivalents 17.11M 38.98M 18.27M 17.79M 37.81M
Total current liabilities 32.43M 33.18M 86.47M 40.17M 25.35M
Current deferred revenue 13.18M 8.55M 5.39M 16.34M 9.87M
Net debt 16.36M -5.51500M 46.13M 43.13M 10.16M
Short term debt 1.12M 1.21M 59.93M 5.44M 0.00000M
Short long term debt - - 58.51M 4.30M -
Short long term debt total 33.47M 33.47M 64.40M 60.92M 47.97M
Other stockholder equity 379.17M 368.85M 320.28M 270.49M 298.64M
Property plant equipment 9.64M 9.92M 10.41M 5.27M 6.39M
Total current assets 44.88M 61.67M 55.72M 32.48M 52.98M
Long term investments - - - - -
Net tangible assets -10.64000M -6.03600M -27.03700M -70.32200M -52.88100M
Short term investments 5.07M 0.00000M 20.28M 0.03M 0.19M
Net receivables 4.59M 3.44M 2.00M 4.70M 4.73M
Long term debt 28.19M 27.89M 0.05M 50.96M 47.97M
Inventory 16.80M 17.95M 13.08M 8.15M 8.57M
Accounts payable 5.86M 6.99M 7.22M 6.50M 5.21M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -30.70400M -29.11600M
Additional paid in capital - - - - -
Common stock total equity - - 0.04M 0.01M 0.15M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -340.82900M -322.55300M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.27M 2.08M 1.80M 1.96M 1.76M
Deferred long term asset charges - - - - -
Non current assets total 10.91M 12.00M 12.21M 12.91M 8.15M
Capital lease obligations 5.29M 5.58M 5.89M 5.67M -
Long term debt total 28.19M 27.89M 0.05M 51.47M 53.26M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -5.03500M 18.92M -20.00000M -0.88300M -0.59100M
Change to liabilities -11.96600M 15.62M -23.93100M -6.84500M 17.12M
Total cashflows from investing activities -5.03500M 18.92M -19.95200M -0.88300M -0.59100M
Net borrowings - -34.12200M -0.21500M -0.21500M -4.75200M
Total cash from financing activities 8.24M 12.08M 46.47M 46.47M -4.75200M
Change to operating activities -0.00500M 0.19M -0.36300M -0.59200M 0.24M
Net income -14.92700M -27.58200M -6.52300M -18.27600M -26.45700M
Change in cash -21.87400M 20.72M 0.47M -20.01600M -13.35500M
Begin period cash flow 38.98M 18.27M 17.79M 37.81M 51.16M
End period cash flow 17.11M 38.98M 18.27M 17.79M 37.81M
Total cash from operating activities -25.00000M -10.28500M -26.10600M -19.35800M -7.74200M
Issuance of capital stock 8.24M 46.20M 46.21M - -
Depreciation 1.09M 1.12M 1.30M 1.62M 1.67M
Other cashflows from investing activities -4.40700M 0.33M 0.70M -0.25600M 0.10M
Dividends paid - - - - -
Change to inventory 1.15M -4.87200M -4.92700M 0.41M -0.73600M
Change to account receivables -1.19400M -1.03200M 2.09M 0.19M -3.09900M
Sale purchase of stock 8.24M 46.20M 46.68M - -
Other cashflows from financing activities 0.00200M 18.92M 0.47M -0.88300M -0.59100M
Change to netincome 0.56M 3.60M 2.77M 0.83M 0.50M
Capital expenditures 0.63M 1.46M 0.66M 0.63M 0.69M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 0.83M 0.50M
Change in working capital -12.01500M 9.90M -27.13000M -6.83500M 13.53M
Stock based compensation 2.08M 2.38M 3.13M 0.83M 0.51M
Other non cash items -1.22900M 3.09M 3.64M 3.37M 3.07M
Free cash flow -25.62800M -11.74400M -26.76100M -19.98500M -8.42800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PLX
Protalix Biotherapeutics Inc		 0.02 1.02% 1.98 20.00 21.37 1.96 3.26 1.63 7.57
NVO
Novo Nordisk A/S		 1.17 2.85% 42.19 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.35 0.85% 41.60 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 2.81 0.63% 445.77 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 4.84 0.79% 616.18 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Protalix Biotherapeutics Inc

2 University Plaza, Hackensack, NJ, United States, 07601

Key Executives

Name Title Year Born
Mr. Dror Bashan Pres, CEO & Director 1967
Mr. Eyal Rubin M.B.A. Sr. VP, CFO, Treasurer & Corp. Sec. 1976
Mr. Yaron Naos Sr. VP of Operations 1964
Ms. Yael Fellous VP of HR NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions